| 1 |
33714285 | Therapeutic effect and mechanism of ibrutinib combined with dexamethasone on multiple myeloma. | 2021 Feb 25 |
1 |
| 2 |
34521277 | Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. | 2021 Dec |
1 |
| 3 |
32435618 | The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. | 2020 |
1 |
| 4 |
33260960 | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment. | 2020 Nov 27 |
1 |
| 5 |
33275735 | Should all newly diagnosed MM patients receive CD38 antibody-based treatment? | 2020 Dec 4 |
1 |
| 6 |
30079070 | CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. | 2018 |
1 |
| 7 |
27611189 | Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. | 2016 |
1 |
| 8 |
18341691 | Regulation of the cd38 promoter in human airway smooth muscle cells by TNF-alpha and dexamethasone. | 2008 Mar 14 |
3 |
| 9 |
18441094 | Glucocorticoid regulation of CD38 expression in human airway smooth muscle cells: role of dual specificity phosphatase 1. | 2008 Jul |
2 |
| 10 |
16291871 | CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferon-gamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. | 2006 Feb |
1 |
| 11 |
16571778 | Transcriptional regulation of CD38 expression by tumor necrosis factor-alpha in human airway smooth muscle cells: role of NF-kappaB and sensitivity to glucocorticoids. | 2006 May |
3 |